Glutamic Acid

Glutamic Acid

SCHEMBL7375280

N[C@@H](CCC(=O)O)C(=O)O.O=C(O)CCN[C@H](CCc1ccccc1)C(=O)O

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 1/20 0.49
GRIK1 P39086 2/20 0.47
GRM8 O00222 1/20 0.47
GRM6 O15303 1/20 0.47
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47
GSR P00390 1/20 0.47
CYP1A2 P05177 1/20 0.47
GRM5 P41594 1/20 0.47
GRIA1 P42261 1/20 0.47
GRIA2 P42262 1/20 0.47
GRIA3 P42263 1/20 0.47
SLC1A3 P43003 1/20 0.47
SLC1A2 P43004 1/20 0.47
SLC1A1 P43005 1/20 0.47
GRIA4 P48058 1/20 0.47
GRIN1 Q05586 1/20 0.47
GRIN2A Q12879 1/20 0.47
GRIK2 Q13002 1/20 0.47
GRIK3 Q13003 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Homophenylalanine SCHEMBL7383933 0.96 GGT1 (0.50) GGT1GRIK1NAALAD2LTA4HMME
SCHEMBL7383218 0.92 GGT1 (0.53) GGT1GRIK1NAALAD2LTA4HMME
Phenylalanine SCHEMBL7432097 0.91 ALPI (0.56) GGT1SLC1A3SLC1A2SLC1A1NAALAD2
Serine SCHEMBL7384366 0.91 GGT1 (0.48) GGT1GRIK1NAALAD2LTA4HMME
SCHEMBL6423726 0.90 GGT1 (0.57) GGT1NAALAD2MMEACEFOLH1
SCHEMBL7382122 0.90 OPRK1 (0.46) GGT1GRIK1NAALAD2MMEACE
Ornithine SCHEMBL7376158 0.90 GGT1 (0.48) GGT1GRIK1GSRLTA4HMME
Norleucine SCHEMBL7430731 0.89 NOD1 (0.48) GGT1GRIK1CYP1A2LTA4HMME
Lysine SCHEMBL7384968 0.89 GGT1 (0.47) GGT1GRIK1GSRLTA4HACE
Asparagine SCHEMBL7375839 0.89 GGT1 (0.46) GGT1GRIK1SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP disclosed
EP-1063991-A1 STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS WARNER-LAMBERT COMPANY LLC (US) 2001-01-03 EP disclosed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO disclosed
EP-0946166-A1 USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING WARNER-LAMBERT COMPANY (US) 1999-10-06 EP disclosed
WO-1999047138-A1 STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS WARNER-LAMBERT COMPANY (US) 1999-09-23 WO disclosed
WO-1998026773-A1 USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING WARNER-LAMBERT COMPANY (US) 1998-06-25 WO disclosed